1-(4-Bromo-3-nitrophenyl)piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(4-Bromo-3-nitrophenyl)piperazine
• 化学式: C10H12BrN3O2
• 分子量: 286.13
• InChiKey: BWYQVTGPLKCNAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  61.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS D'OXAZOLE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
  申请人：LIFEARC

  公开号：WO2018122549A1

  公开（公告）日：2018-07-05

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, • B is a saturated or partially unsaturated monocyclic or bicyclic, heterocyclic group optionally substituted by one or more R 10 groups; * X is selected from SO2, CO2, CO, CONR11 and (CR12 R13) p. Said compounds are capable of inhibiting PAICS and are useful in the treatment of proliferative disorders. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formula (I).

  本发明的第一个方面涉及式(I)的化合物，或其药学上可接受的盐或酯，• B是一个饱和或部分不饱和的单环或双环，杂环基，可选地由一个或多个R10基团取代；* X从SO2，CO2，CO，CONR11和(CR12R13)p中选择。所述化合物能够抑制PAICS，并且在治疗增生性疾病方面是有用的。进一步方面涉及制药组合物、治疗用途和制备式(I)化合物的过程。
• Oxazole derivatives for use in the treatment of cancer
  申请人：LIFEARC

  公开号：US10961233B2

  公开（公告）日：2021-03-30

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, • B is a saturated or partially unsaturated monocyclic or bicyclic, heterocyclic group optionally substituted by one or more R 10 groups; *X is selected from SO2, CO2, CO, CONR11 and (CR12R13) p. Said compounds are capable of inhibiting PAICS and are useful in the treatment of proliferative disorders. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formula (I).

  本发明的第一个方面涉及式（I）化合物或其药学上可接受的盐或酯，-B是饱和或部分不饱和的单环或双环、杂环基团，任选被一个或多个R 10基团取代；*X选自SO2、CO2、CO、CONR11和(CR12R13)p。其他方面涉及药物组合物、治疗用途和制备式（I）化合物的工艺。
• OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER
  申请人：LifeArc

  公开号：EP3562824A1

  公开（公告）日：2019-11-06
• COMPOUND FOR SIMULTANEOUSLY INHIBITING LSD1 AND HDAC TARGETS AND APPLICATION THEREOF
  申请人：PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL

  公开号：US20200331882A1

  公开（公告）日：2020-10-22

  A compound having a general structural formula as shown in Formula I: X-AB-Y (Formula I); in the above Formula I, X is selected from any one of —CO2H, —CONHZ, —CH═CH—CO2H, —CH═CH—CONHZ, wherein Z is selected from any one of substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted aryl, and hydroxyl; Y=—NR1R2, wherein NR1R2 is a substituted or unsubstituted 3- to 9-membered nitrogen-containing heterocycloalkyl; A and B are each independently selected from substituted or unsubstituted phenylene, substituted or unsubstituted azaphenylene. The compound or corresponding pharmaceutical salt thereof can inhibit LSD1 and HDAC target proteins at the same time, thus inhibit the proliferation of many kinds of tumor cells and have good antitumor effect.